Beranda › Miastenia Gravis › California
Uji klinis Miastenia Gravis di California
20 studi untuk Miastenia Gravis mencari peserta di lokasi di California.
Kota di California
- Orange6 studi
- San Francisco6 studi
- Los Angeles4 studi
- Mountain View4 studi
- Carlsbad3 studi
- Pasadena3 studi
Teks studi resmi (Bahasa Inggris)
Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis
- Neurology Center of North Orange County, Fullerton
- The Neurology Group, Pomona
Menerima pesertaFase 3
Usia 18 hingga 74 · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT07217587A Phase 3 Study to Evaluate Claseprubart in Adults With Generalized Myasthenia Gravis (EMERGE)
- Cinical Study Site, Pasadena
Menerima pesertaFase 3
Usia 18 hingga 80 · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT07647510ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis
- Profound Research LLC - Carlsbad, Carlsbad
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 24 Sep 2026 · NCT07294170ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
- Profound Research LLC - Carlsbad, Carlsbad
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 24 Sep 2026 · NCT07284420A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis
- Tri Valley Neurology Medical Associates Inc., Mission Hills
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 11 Sep 2026 · NCT07501702A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders
- TG Therapeutics Investigational Trial Site, La Jolla
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 9 Sep 2026 · NCT06680037Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis
- University of California Irvine Medical Center, Irvine
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 21 Agu 2026 · NCT06414954A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases
- Hoag Memorial Hospital Presbyterian, Newport Beach
- Stanford Neuroscience Health Center, Palo Alto
Menerima pesertaFase 1
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 14 Agu 2026 · NCT07304154RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis
- University of California Irvine, Orange
- UC Davis, Department of Neurology, Sacramento
- University of California, San Francisco, San Francisco
Menerima pesertaFase 1/2
Usia 18 hingga 70 · Semua jenis kelamin · Diperbarui 13 Agu 2026 · NCT06359041Pregnancy Registry, Infants, Serum/Milk Analysis (PRISMA)
- University of California-San Francisco, San Francisco
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Usia 18 hingga 64 · Wanita · Diperbarui 11 Agu 2026 · NCT06940323Study of Aritinercept in Patients With Generalized Myasthenia Gravis
- Aurinia Investigational Site, Pasadena
Menerima pesertaFase 1/2
Usia 18 hingga 85 · Semua jenis kelamin · Diperbarui 3 Agu 2026 · NCT07596901A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis
- Lucile Packard Children's Hospital Stanford, Palo Alto
- UCSF Benioff Children's Hospital, San Francisco
Menerima pesertaFase 2/3
Usia 2 hingga 17 · Semua jenis kelamin · Diperbarui 31 Jul 2026 · NCT05265273Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
- Site Number - 1010, Carlsbad
- Site Number - 1028, Irvine
- Site Number - 1023, Los Angeles
- dan 2 lainnya
Menerima pesertaFase 3
Usia 18 hingga 80 · Semua jenis kelamin · Diperbarui 30 Jul 2026 · NCT07039916KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis
- Ronald Reagan UCLA Medical Center, Los Angeles
- University of California, Irvine, Orange
- Stanford University Medical Center, Palo Alto
Menerima pesertaFase 2/3
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 29 Jul 2026 · NCT06193889A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
- Care Access Research, Pasadena
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 27 Jul 2026 · NCT04951622A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)
- University of Southern California, Los Angeles
- University of California Irvine, Orange
- University of California San Francisco (UCSF), San Francisco
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 18 Jun 2026 · NCT06456580A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases
- UCLA Medical Center, Los Angeles
- University of California, Irvine, Orange
- Stanford Hospital, Palo Alto
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Feb 2026 · NCT06626919Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)
- Clinical Trial Site, Fresno
- Clinical Trial Site, Orange
- Clinical Trial Site, Rancho Mirage
- dan 1 lainnya
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 18 Feb 2026 · NCT04202341A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa
- UCSF Medical Center - Helen Diller Family Comprehensive Cancer Center - Brain Tumor Center,, San Francisco
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 17 Feb 2026 · NCT06298565Vitaccess Real MG Registry
- UCI Health, Orange
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 29 Jul 2025 · NCT06064461Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.